Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens | Zendy

Mark Biagi | Zendy; Aisha Shajee | Zendy; A. Vialichka | Zendy; M. Jurkovic | Zendy; X. Tan | Zendy; Eric Wenzler | Zendy

Open Access

Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens

Author(s) -

Mark Biagi,

Aisha Shajee,

A. Vialichka,

M. Jurkovic,

X. Tan,

Eric Wenzler

Publication year - 2020

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02255-19

Subject(s) - serratia marcescens , meropenem , ceftazidime/avibactam , microbiology and biotechnology , imipenem , carbapenem , broth microdilution , ceftazidime , enterobacteriaceae , serratia , antibacterial agent , biology , medicine , antibiotics , bacteria , antibiotic resistance , minimum inhibitory concentration , escherichia coli , pseudomonas aeruginosa , pseudomonas , biochemistry , genetics , gene

The Serratia marcescens enzyme (SME) is a chromosomally encoded carbapenemase with no known optimal treatment. Various β-lactam/β-lactamase inhibitors and comparators were evaluated against 8 SME producers via broth microdilution. Four isolates were subsequently tested via time-kill analyses. All isolates were resistant to imipenem, imipenem-relebactam, and meropenem but susceptible to ceftazidime, ceftazidime-avibactam, and meropenem-vaborbactam. Ceftazidime, imipenem-relebactam, and meropenem-vaborbactam were bactericidal against 3, 0, and 4 isolates, respectively. Meropenem-vaborbactam may be a potential option for severe SME-producing infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research